Trial Profile
The Efficacy and Safety of Benralizumab In the Treatment of Eosinophilic Grandulomatosis With Polyangiitis (EGPA) Study: BITE
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma; Granulomatosis
- Focus Adverse reactions
- Acronyms BITE
- 04 Mar 2021 Planned End Date changed from 1 Dec 2018 to 1 Dec 2021.
- 04 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 08 May 2017 Status changed from not yet recruiting to recruiting.